Q-omics provides the consensus-scored SNX22 profile across patient tissues and cancer cell-line models. SNX22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SNX22 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SNX22 RNA expression shows 18,219 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where SNX22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX22 survival associations across molecular data types. SNX22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX22 RNA expression–survival associations across cancer types. High SNX22 expression shows unfavorable associations in UVM, ACC, KICH and UCS, but favorable associations in LUAD and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SNX22 RNA expression.
This table summarizes SNX22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SNX22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX22 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, LIHC and THCA. The KIRC box plot shows higher SNX22 RNA expression in tumor versus normal tissue (log2 FC = +0.820, t-test p < 0.001).
This table shows molecular features associated with SNX22 in patient tissues and cancer cell lines. In patient samples, SNX22 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SNX22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
